


1. I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596704489 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2. Dated: June 27, 2007

3. Signature:  (Lori Sims)

Patent  
Docket No. 475512000400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Steven M. WATKINS

Examiner: S. Saucier

Serial No.: 10/808,880

Group Art Unit: 1651

Filing Date: March 24, 2004

For: METHODS OF USING QUANTITATIVE  
LIPID METABOLOME DATA

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

**This Supplemental Information Disclosure Statement is submitted:**

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of \_\_ is enclosed.
- ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other


Application Serial No. 10/808,880

Patent  
Docket No. 475512000400

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**  
referencing 475512000400.

Dated: June 27, 2007

Respectfully submitted,

By   
Alicia J. Hager  
Registration No.: 44,140

MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-4296



ALTERNATIVE TO PTO/SB/08A/B (09/06)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/808,880
				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	1	of	1	Attorney Docket Number	475512000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	Edvardsson, U. et al. (2003). "Hepatic Protein Expression of Lean Mice and Obese Diabetic Mice Treated with Peroxisome Proliferator-activated Receptor Activators," <i>Proteomics</i> 3:468-478.	
	2.	Ferrand, C. et al. (2006). "Prolonged Treatment with the $\beta_3$ -adrenergic Agonist CL 316243 Induces Adipose Tissue Remodeling in Rat but not in Guinea Pig: 1) Fat Store Depletion and Desensitization of $\beta$ -adrenergic Responses," <i>J. Physiol. Biochem.</i> 62(2):89-99.	
	3.	McTernan, P.G. et al. (May 2002). "Insulin and Rosiglitazone Regulation of Lipolysis and Lipogenesis in Human Adipose Tissue in Vitro," <i>Diabetes</i> 51:1493-1498.	
	4.	Nichols, G.A. et al. (2007). "Weight Changes Following the Initiation of New Anti-hyperglycaemic Therapies," <i>Diabetes, Obesity and Metabolism</i> 9:96-102.	
	5.	Patel, N.G. et al. (January 2003). "Differential Regulation of Lipogenesis and Leptin Production by Independent Signaling Pathways and Rosiglitazone During Human Adipocyte Differentiation," <i>Diabetes</i> 52:43-50.	
	6.	Phinney, S.D. et al. (October 1995). "Evidence for Increasing Lipogenesis with BMI and Following Eucaloric High Carbohydrate Feeding in Women," <i>Obesity Research</i> , NAASO-SSIB Annual Meeting, Baton Rouge, LA, 3(Suppl. 3): Abstract O83.	
	7.	Siguel, E. (June 30, 1998). "Diagnosing Essential Fatty Acid Deficiency," <i>Circulation</i> 97(25):2580-2583.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 1140637